Laughing Gas, Viagra, and Lipitor

Total Page:16

File Type:pdf, Size:1020Kb

Laughing Gas, Viagra, and Lipitor Laughing Gas, Viagra, and Lipitor The Human Stories Behind the Drugs We Use Jie Jack Li 1 2006 3 Oxford University Press, Inc., publishes works that further Oxford University’s objective of excellence in research, scholarship, and education. Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi New Delhi Shanghai Taipei Toronto With offices in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam Copyright © 2006 by Oxford University Press Published by Oxford University Press, Inc. 198 Madison Avenue, New York, New York 10016 www.oup.com Oxford is a registered trademark of Oxford University Press All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press. Library of Congress Cataloging-in-Publication Data Li, Jie Jack. Laughing gas, viagra, and lipitor : the human stories behind the drugs we use / Jie Jack Li. p. cm. Includes bibliographical references and index. ISBN-13 978-0-19-530099-4 ISBN 0-19-530099-8 1. Drugs—Miscellanea. 2. Nitrous oxide. 3. Sildenafil. I. Title. RM301.15.L5 2006 362.29'9—dc22 2006002586 987654321 Printed in the United States of America on acid-free paper foreword ny person interested in understanding the history of medical A progress and the way in which many of the most important medi- cines came into existence will be well rewarded by reading this latest book by Jie Jack Li, one of the most prolific and interesting authors in the field of molecular medicine and chemistry. And if that person happened to be aiming for or beginning a career in medicinal discovery, he or she would gain even more by so doing. The many case histories within this book contain a large number of valuable take-home lessons and extraordinary insights that have emerged from a spectrum of research over many years in medicinal science, or what can now be called molecular medicine. These stories reveal not only the complexity, unpredictability, and chal- lenges of the discovery process but also the intellectual and human quali- ties upon which success depended. I found this to be a most inspiring, engaging, and broadening reading experience, and I cannot imagine that this sense of reward would not be shared by most individuals who want to know more about health sciences, creativity, discovery, and just plain luck (good and bad). It is unimaginably difficult (and now very costly) to discover an impor- tant new therapeutic agent. Most people who have engaged in this effort for a lifetime have not been so fortunate. It is not easy to select a research objective that will turn out to be a winner. The enormous complexity of the human body (especially in molecular terms), the depth of our igno- rance in the molecular and biological sciences, and the lack of more pow- erful and yet to be discovered scientific research tools all conspire, like the fog of war, to obscure our vision in the search for a great new discovery. So one needs not only keen intellect and extraordinary personal qualities to be successful but also as much perspective, perception, and intuition as one can muster. This book provides a clear picture of these human elements behind success. As a bonus, it is also entertaining and enjoyable to read. It will be gratifying if the future audience for this fine work includes a wide swath of the general public, as they too will be fascinated by the in- ner workings of research at the frontier. E. J. Corey June 2005 Cambridge, Massachusetts Over the course of the past century, science has made such tremendous progress in the battle against human disease that many of the ailments that were lethal to our ancestors no longer pose a threat to us. Yet, for most people living in modern society, the process by which such a tremendous revolution has taken place remains a mystery, with drugs merely constitut- ing a pill or liquid prescribed by a doctor and bought at a pharmacy. Laughing Gas, Viagra, and Lipitor: The Human Stories Behind the Drugs We Use fills this gap beautifully. Through a series of enlightening and highly entertaining chapters, Jie Jack Li takes the reader on an unparalleled journey through the history of drugs, a trip that conveys both the science underlying the discovery and the personalities and drama that accompany them. Each section glows with behind-the-scenes glimpses at the brilliance, passion, and frailty of the people involved in the discoveries, from early pioneers to the heroic and landmark team efforts of today’s pharmaceutical companies that amalgamate the expertise of scientists in such diverse fields as synthetic chemistry, biology, pharmacokinetics, drug metabolism, and toxicology. What is particularly striking in chapter after chapter is the astonishing and sometimes chilling role that serendipity plays in the drug discovery pro- cess. For instance, how many people would have died from bacterial infec- tion had Fleming covered his petri dish while on vacation, or had the first in vivo studies of penicillin been performed on guinea pigs (as penicillin is toxic to them)? How many people know that the discovery of digitalis, used for the treatment of congenital heart failure, arose from a young lady’s love of flowers? These questions offer just a glimpse of the many hidden treasures that lie within this text. I offer my heartiest congratulations to Dr. Li for x foreword writing a uniquely original book that is a joy to read and that will un- doubtedly serve as an inspiration for scientists who are tirelessly at work developing the cures of the future and for students who aspire to such a noble cause. Phil S. Baran April 2005 La Jolla, California foreword xi preface his is a book on the history of drug discovery. More important, this is Ta book about drug discoverers that highlights their intellectual splen- dor, as well as their human frailty. Emil Fischer, perhaps the greatest or- ganic chemist ever, once stated: “Science is not an abstraction; but as a product of human endeavor it is inseparably bound up in its development with the personalities and fortunes of those who dedicate themselves to it.” In his book Ascent of Man, Jacob Bronowski wrote: “Discoveries are made by men, not merely by minds, so that they are alive and charged with indi- viduality.”1 When I set out to take on this project, I did not intend to write another scholarly tome—various topics have been published extensively in specialized areas of medical history. In contrast, I wanted to place emphasis on the human aspect of drug discovery by telling fascinating stories about the discoverers: their aspirations and activities, their hard work and frustra- tions, their hopes and fears, their setbacks and triumphs. History is replete with examples of breakthrough medicines that have saved millions of lives. The discovery of ether as an anesthetic by Morton, of penicillin as an an- tibiotic by Fleming, and of insulin for diabetes by Banting are just a few ex- amples. The discoverers of these medicines are certainly benefactors to mankind—for instance, without penicillin, 75% of us probably would not be alive and reading this book, because some of our parents or grandparents would have succumbed to infections. On the other hand, as a testimony to human frailty, some of the scientists suffered misunderstanding, antipathy, and heartbreak. Some of them turned from collaborators into acrimonious scientific rivals. As is often the case, reality is more dramatic than fiction. I strongly believe that man, if given enough time, can overcome any medical problem. The future seemed seriously grim when AIDS became an epidemic 20 years ago. Now the advent of HIV protease inhibitors and reverse transcriptase inhibitors as antiviral agents have transformed AIDS from a death sentence to a disease that can be controlled. In preparing this manuscript, I have had the great fortune to communicate with some scientists who played pivotal roles in discover- ing the drugs we use. They are Steven J. Brickner and Michael R. Bar- bachyn (Zyvox); Carl Djerassi (norethindrone); V. Craig Jordan (Tamoxifen); Bruce D. Roth (Lipitor); Nicholas K. Terrett (Viagra); Joseph Vacca (Crixivan); Robert Vince (Ziagen), and Jürg Zimmermann (Gleevec). There have been many myths and inaccuracies associated with these well-known drugs. The inventors’ perspectives afford this book invaluable accuracy and insight, because history is not history un- less it is true. Drug discovery often involves many people across many disciplines— teamwork is of paramount importance. In this manuscript, I have of- ten focused on the key players in the discovery of drugs. This is in no way meant to marginalize collaborations essential to the success of the venture. In preparing this manuscript, I have also incurred many debts of gratitude to my academic friends, E. J. Corey at Harvard University and Phil S. Baran at Scripps Research Institute, who have provided much en- thusiastic encouragement. Corey, a Nobel laureate in chemistry, read the entire manuscript and provided countless invaluable comments and sug- gestions. My friends in industry, Danielle Mills, Lorna H. Mitchell, Bruce D. Roth, and Dennis Vargo, also proofread the entire manuscript and offered numerous suggestions for improvements in terms of both science and English. Roth and Vargo, both veterans in the pharmaceuti- cal industry, afforded precious insight into drug discovery. Friends and colleagues who also proofread portions of the manuscript are: Narendra Ambhaikar, Emily Andrews, Noah Burns, Michael DeMartino, Ben Hafensteiner, Douglas S.
Recommended publications
  • University of Groningen the Pill and Thrombosis Van Vlijmen, Elizabeth
    University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 08-10-2021 Financial support for the printing of this thesis was kindly provided by the Dutch Medicines Evaluation Board and UMCG/GUIDE.
    [Show full text]
  • The Early History of Medical Genetics in Canada William Leeming OCAD University [email protected]
    OCAD University Open Research Repository Faculty of Liberal Arts & Sciences and School of Interdisciplinary Studies 2004 The Early History of Medical Genetics in Canada William Leeming OCAD University [email protected] © Oxford University Press. This is the author's version of the work. It is posted here for your personal use. Not for redistribution. Original source at DOI: 10.1093/shm/17.3.481. Recommended citation: Leeming, W. “The Early History of Medical Genetics in Canada.” Social History of Medicine 17.3 (2004): 481–500. Web. Leeming, W. (2004). The early history of medical genetics in Canada. Social History of Medicine, 17(3), 481-500. Pre-Publication Draft The Early History of Medical Genetics in Canada Abstract: This article shows that the intellectual and specialist movements that supported the growth of medical genetics in Canada between 1947 and 1990 were emergent phenomena, created, split, and reattached to different groups of actors, and reconfigured numerous times over the course of four decades. In each instance, new kinds of working relationships appeared; sets of diverse actors in local university- hospital settings coalesced into a new collectivity; and, as a collectivity, actors defined and/or redefined occupational roles and work rules. In its beginnings, medical genetics appears to be the object of a serious institutional manoeuver: a movement in support of the creation of examining and teaching positions in human genetics in North American medical schools. With time, the institutionalization of ‘medical genetics’ took hold, spurred on by changes in the rate and direction of service delivery associated with genetic consultation and laboratory services in clinical settings.
    [Show full text]
  • Special Edition Inside
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Inside: Feature articles from 2014-2015 Special Edition VISIT THE ASPET CAREER CENTER TODAY! WWW.ASPET.ORG/CAREERCENTER/ 4 5 12 21 30 41 WHAT YOU NEED: ASPET’S CAREER CENTER HAS IT 52 Jobseekers: Employers: No registration fee Searchable résumé database Advanced search options Hassle-free posting; online account management tools 61 Sign up for automatic email notifi cations of new jobs that Reach ASPET’s Twitter followers (over 1,000), match your criteria LinkedIn Members (over 2,000), and email subscribers (over 4,000) Free & confi dential résumé posting 71 Post to just ASPET or to entire NHCN network Access to jobs posted on the National Healthcare Career Network (NHCN) Sign up for automatic email notifications of new résumés that match your criteria Career management resources including career tips, coaching, résumé writing, online profi le development, Job activity tracking and much more ASPET is committed to your success: The ASPET Career Center is the best resource for matching job seekers and employers in the pharmacology and related health science fi elds. Our vast range of resources and tools will help you look for jobs, fi nd great employees, and proactively manage 9650 Rockville Pike, Bethesda, MD 20814-3995 your career goals. Main Office: 301.634.7060 www.aspet.org ASPET Career Center Full Page Ad 2015 Updated.indd 1 1/15/2016 3:18:16 PM The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. THE PHARMACOLOGIST VISIT THE ASPET CAREER CENTER TODAY! PRODUCTION TEAM Rich Dodenhoff Catherine Fry, PhD WWW.ASPET.ORG/CAREERCENTER/ Judith A.
    [Show full text]
  • C:\Users\Carolanne\Documents
    If you are having trouble viewing this email, please select here. January 25, 2012 Vol. 20, No. 10 From Banting and Best's discovery of insulin, to Till and McCullough's stem cell breakthrough, the University of Toronto Faculty of Medicine has an incredible legacy of visionary, ground-breaking research. Medical advances traced back to our labs have made countless real-world improvements in patient therapies and care. Together with our TAHSN partners, we truly are a national and international research powerhouse. Ranked 4th for research in Clinical Medicine among World Universities by the Higher Education Council of Taiwan, we are home to 125 Canada Research Chairs, 2 Canada Excellence in Research Chairs, and over 2000 masters and doctoral students who are critical to our research capacity. On January 24, our medical students presented 170 research posters and several oral presentations at their annual research day - a remarkable demonstration of the interest and engagement of our students in scientific enquiry. With the fundamentals in place, there is a tremendous opportunity in Canada to lead the future development of the health research agenda worldwide. But it is not sufficient to do what we have always done. Leadership in the health research of tomorrow will require us to adapt to new realities - where leading-edge investigation takes place across systems and disciplines, and where data can be collected and shared in ways we have not previously envisioned and on a scale we have never before seen. We must create new structures that break down old silos and allow the broad sharing of knowledge.
    [Show full text]
  • Schwerpunkt 40 Jahre Pille
    Familienplanungs- RUNDBRIEF Ausgabe Juni 2000 Nr. 1/2 Inhalt Einleitung 3 Hormonelle Kontrazeption: 40 Jahre Pille 4 – Entwicklungen, die zur Herstellung der Pille führten 4 – Weiterentwicklung der Pille von 1960 bis heute 8 – Die gesellschaftspolitische Bedeutung der Pille 12 – Hormonelle Kontrazeptiva heute in Deutschland 14 – Anwendung der hormonalen Kontrazeptiva nach dem heutigen 17 Wissensstand – Wechselwirkungen 24 Anhang (Ende des Dokuments) – Medikamente, die die Sicherheit A1 der Pille beeinträchtigen können – Liste hormonaler Kontrazeptiva A2 IPPF Informationen – Gestagen-Implantate 27 Forum – Vorgeburtliche Untersuchungen: 28 Möglichkeiten und Grenzen Veranstaltungskalender 29 Stichwortverzeichnis 1999 31 Deutsche Gesellschaft für Familienplanung, Sexualpädagogik und Sexualberatung e.V., Bundesverband e.V., Sexualberatung und Sexualpädagogik für Familienplanung, Gesellschaft Deutsche Stresemannallee 3, 60596 Frankfurt am Main, Telefon 069/639002 Impressum: 2000 Herausgeber: PRO FAMILIA-Bundesverband Redaktion: Dr. med. Ruth Eichmann, Frankfurt am Main Dr. med. Ines Thonke, Frankfurt am Main Dr. med. Jutta Walter, Heidelberg Anschrift: PRO FAMILIA-Bundesverband Stresemannallee 3 60596 Frankfurt am Main Gefördert von der Bundeszentrale für gesundheitliche Aufklärung (BZgA). Familienplanungs- RUNDBRIEF Juni 2000 Nr. 1/2 3 In der Rubrik „HINWEISE“ wird wie üblich in dem Einleitung jeweiligen Familienplanungs-Rundbrief Aktuelles aus der Medizin zu finden sein, das von besonde- rer Bedeutung für die Beratungspraxis ist. Lite- raturneuerscheinungen und Ankündigungen von Veranstaltungen runden die einzelnen Familien- planungs-Rundbriefe ab. In Übereinstimmung mit der gewohnten Gliede- rung befasst sich der erste Familienplanungs- Beibehalten wird ferner der Abschnitt, in welchem Rundbrief des Jahres mit einer Vorschau auf die aktuelle Informationen der IPPF (International im laufenden Jahr geplanten Schwerpunktthe- Planned Parenthood Federation) aufgenommen men. Dafür vorgesehen sind: werden, soweit sie medizinischen Inhalts sind.
    [Show full text]
  • Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by William E. Bunney, Jr
    1 RECOLLECTIONS OF THE HISTORY OF NEUROPSYCHOPHARMACOLOGY THROUGH INTERVIEWS CONDUCTED BY WILLIAM E. BUNNEY, JR. Edited by Peter R. Martin International Network for the History of Neuropsychopharmacology Risskov 2016 2 William E. Bunney, Jr. (circa 1980) 3 Contents PREFACE ..................................................................................................................................................... 4 1. THOMAS A. BAN ............................................................................................................................... 9 2. ARVID CARLSSON .......................................................................................................................... 28 3. JOSEPH T. COYLE ............................................................................................................................ 38 4. ELLEN FRANK ................................................................................................................................. 55 5. J. CHRISTIAN GILLIN ..................................................................................................................... 66 6. LOUIS A. GOTTSCHALK ................................................................................................................ 78 7. SALOMON Z. LANGER ................................................................................................................... 89 8. HEINZ E. LEHMANN ....................................................................................................................
    [Show full text]
  • Chinese Terracotta Warriors
    28 How Paul Janssen’s Drugs Saved the CCHHIINNEESSEE TTEERRRRAACCOOTTTTAA WWAARRRRIIOORRSS Rebecca J. Anderson The Chinese Terracotta Army, dating from approximately the late third century BCE, was discovered on March 29, 1974 to the east of Xi’an in Shaanxi Province, China. Photo: Shutterstock The Pharmacologist • March 2015 29 Chinese museum officials gazed with dismay at their Janssen label (3). These included repackaging and priceless army of ancient statues. For 22 centuries, the distributing generic penicillin and sulfonamides, which terracotta warriors had been protected and preserved in the were increasingly in demand after the war. Paul’s mother, soil of China’s Yellow River valley (1). Now, less than 20 Margriet Fleerakers, served as office manager and also years after these old soldiers emerged from their supervised the production line, including quality control (3). subterranean fortress, many of them had become infected Paul finished high school in 1943. To avoid forced and were suffering from a mysterious rash (2). Local labor in the German factories, he secretly enrolled in archeologists suspected the warriors’ moldy rash was due to college (at the age of 16) with the help of his uncle, Emiel fungi, but they lacked specialized laboratory equipment and Janssen (3). The 12 Jesuit teachers at the Faculté Notre- had only limited expertise to diagnose and treat the ailment. Dame de la Paix in Namur, Belgium, offered intensive The detective who stepped forward to solve this courses in physics, biology, philosophy, and chemistry to a mystery and thwart an archeological catastrophe was an handful of students, including Paul, without the knowledge unlikely hero: a businessman, physician, and scientist who of the German occupiers (2, 3).
    [Show full text]
  • Escitalopram
    ESCITALOPRAM Study for Self Portrait, pencil and charcoal on paper, Edgar Degas, 1855 What Edgar does not tell Mary…. That sometimes he cannot sleep at night because he is dreaming of gouache, lithography, pastel, monotype, charcoal, oil, etchings, plates, wax. That he wants to stop and start time at his prerogative so that he can revel in the bounty of materials, van challenge himself and experiment without time passing because the day isn’t long enough. That the circus or the Opera ballet, or the cafe chantants or dinners with friends or the delicious masculine embrace of the racetrack devour his evenings and Sundays but in between there is only work. That some days he looks up and hours have passed and he is late for one thing or another and he races to the cafe or the friends or the theater and what he leaves behind is unfinished work, and he thinks nothing he makes will ever be finished. That he must make careful calculations in order to produce his articles because he is not gifted, he is not prescient, he is not an auteur, he is only a draftsman, a servant, a plodding poseur who wishes to excel. That he is hampered by the infernal blur in his eye he fears will only spread. That the arrangement of legs on a group of dancers or the colour of skirt sashes or the depth of the stage or the bend of a laundress’s back or the line of her apron confounds him and has to be worked and reworked.
    [Show full text]
  • Using a Novel Optogenetic Approach to Directly Assess 5-Ht1a
    Wayne State University Wayne State University Dissertations 1-1-2015 Using A Novel Optogenetic Approach To Directly Assess 5-Ht1a Somatodendritic Autoreceptor Function In Response To Chronic Selective Serotonin Reuptake Inhibitor Treatment Kelly Marie Mcgregor Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Neurosciences Commons, Pharmacology Commons, and the Psychiatric and Mental Health Commons Recommended Citation Mcgregor, Kelly Marie, "Using A Novel Optogenetic Approach To Directly Assess 5-Ht1a Somatodendritic Autoreceptor Function In Response To Chronic Selective Serotonin Reuptake Inhibitor Treatment" (2015). Wayne State University Dissertations. Paper 1316. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. USING A NOVEL OPTOGENETIC APPROACH TO DIRECTLY ASSESS 5-HT1A SOMATODENDRITIC AUTORECEPTOR FUNCTION IN RESPONSE TO CHRONIC SELECTIVE SEROTONIN REUPTAKE INHIBITOR TREATMENT by KELLY MARIE MCGREGOR DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2015 MAJOR: PHARMACOLOGY (Molecular Neuropharmacology) Approved By: ________________________________________ Advisor Date ________________________________________ ________________________________________
    [Show full text]
  • ANNUAL REPORT 1981-1982 Montreal Neurological Hospital Montreal Neurological Institute
    VAll ANNUAL REPORT 1981-1982 Montreal Neurological Hospital Montreal Neurological Institute 47th Annual Report Montreal Neurological Hospital Montreal Neurological Institute 1981-1982 (Version francaise disponible sur demande.) Table of Contents Montreal Neurological Hospital Neurogenetics 86 Board of the Corporation 7 Neuromuscular Research 89 Board of Directors 8 Neuro-ophthalmology 91 Council of Physicians Executive 10 Neuropharmacology 92 Clinical and Laboratory Staff 12 Research Computing 94 Consulting and Visiting Staff 17 William Cone Laboratory 95 Professional Advisors 19 Resident and Rotator Staff 20 Education Clinical and Laboratory Fellows 21 Clinical Training Opportunities 101 Nursing Administration and Courses of Instruction 105 Education 23 Post-Basic Nursing Program 107 Graduates of Post-Basic Nursing Program 25 Publications 111 Administrative Staff 26 Supervisory Officers 26 Finances Executive of the Friends of the Neuro Montreal Neurological Hospital 127 27 Montreal Neurological Institute 131 Clergy 27 Endowments 132 Grants for Special Projects 133 Montreal Neurological Institute MNI Grants 135 Neurosciences Advisory Council 31 Donations 136 Advisory Board 32 Suggested Forms for Bequests 139 Scientific Staff 34 Academic Appointments, McGill 36 Statistics Executive Committee 40 Classification of Operations 143 Research Fellows 41 Diagnoses 146 Causes of Death 147 Director's Report 45 Hospital Reports Neurology 53 Neurosurgery 55 Council of Physicians 57 Nursing 59 Administration 62 Finance 64 Social Work 65 Institute Reports El El Experimental Neurophysiology 74 Fellows' Library 77 Muscle Biochemistry 78 Neuroanatomy 80 Neurochemistry 82 Montreal Neurological Hospital In April 1983 Dr. William Feindel, director of the Montreal Neurological Institute and director-general of the Montreal Neurological Hospital was named an officer of the Order of Canada.
    [Show full text]
  • 1976-77-Annual-Report.Pdf
    TheCanada Council Members Michelle Tisseyre Elizabeth Yeigh Gertrude Laing John James MacDonaId Audrey Thomas Mavor Moore (Chairman) (resigned March 21, (until September 1976) (Member of the Michel Bélanger 1977) Gilles Tremblay Council) (Vice-Chairman) Eric McLean Anna Wyman Robert Rivard Nini Baird Mavor Moore (until September 1976) (Member of the David Owen Carrigan Roland Parenteau Rudy Wiebe Council) (from May 26,1977) Paul B. Park John Wood Dorothy Corrigan John C. Parkin Advisory Academic Pane1 Guita Falardeau Christopher Pratt Milan V. Dimic Claude Lévesque John W. Grace Robert Rivard (Chairman) Robert Law McDougall Marjorie Johnston Thomas Symons Richard Salisbury Romain Paquette Douglas T. Kenny Norman Ward (Vice-Chairman) James Russell Eva Kushner Ronald J. Burke Laurent Santerre Investment Committee Jean Burnet Edward F. Sheffield Frank E. Case Allan Hockin William H. R. Charles Mary J. Wright (Chairman) Gertrude Laing J. C. Courtney Douglas T. Kenny Michel Bélanger Raymond Primeau Louise Dechêne (Member of the Gérard Dion Council) Advisory Arts Pane1 Harry C. Eastman Eva Kushner Robert Creech John Hirsch John E. Flint (Member of the (Chairman) (until September 1976) Jack Graham Council) Albert Millaire Gary Karr Renée Legris (Vice-Chairman) Jean-Pierre Lefebvre Executive Committee for the Bruno Bobak Jacqueline Lemieux- Canadian Commission for Unesco (until September 1976) Lope2 John Boyle Phyllis Mailing L. H. Cragg Napoléon LeBlanc Jacques Brault Ray Michal (Chairman) Paul B. Park Roch Carrier John Neville Vianney Décarie Lucien Perras Joe Fafard Michael Ondaatje (Vice-Chairman) John Roberts Bruce Ferguson P. K. Page Jacques Asselin Céline Saint-Pierre Suzanne Garceau Richard Rutherford Paul Bélanger Charles Lussier (until August 1976) Michael Snow Bert E.
    [Show full text]
  • The Chemistry Enterprise in 2015
    The Chemistry Enterprise in 2015 William F. Carroll, Jr., Occidental Chemical Corp., ACS President 2005 Douglas J. Raber, GreenPoint Science ACKNOWLEDGMENT First, we would like to thank the members of the Senior Analysis. Thanks to those chemists who contributed specific Advisory Group who were interviewed extensively to com- predictions contained in the paper itself. Finally, thanks to all prise the first part of the project, the Situation Analysis. In the ACS members and staff who participated in or facilitated addition, we thank the Governance Advisory Team who dialog and debate; you provided the engine to bring the helped us with the strategy and peer review of the Situation Enterprise Project to completion. Senior Advisory Group Governance Advisory Team Samuel W. Bodman, Alvin L. Kwiram, Michael Betenbaugh, C. Dale Poulter, Deputy Secretary, U.S. University of Washington Johns Hopkins University University of Utah Department of the Treasury Robert S. Langer, Chris Hollinsed, Carolyn Ribes, Ronald Breslow, Massachusetts Institute of DuPont Co. Dow Chemical Co. Columbia University Technology Michael Jaffe, Ron Webb, Donald M. Burland, Jeffrey M. Lipton, New Jersey Institute of Procter & Gamble National Science Foundation Nova Chemicals Technology Marinda Wu, Ralph J. Cicerone, Thomas E. Reilly, Jr., Michael Nevill, Science is Fun! University of California, Irvine American Chemistry Council Solvay America, Inc. Thomas E. D’Ambra, Alfred P. Sattelberger, Albany Molecular Research, Inc. Los Alamos National Laboratory Predictions Peter B. Dervan, Jay Short, California Institute of Technology Diversa Corp. Ronald Breslow, Simon Campbell, Arthur B. Ellis, Jeffrey J. Siirola, Columbia University Royal Society of Chemistry National Science Foundation Eastman Chemical Co.
    [Show full text]